Yahoo · Sep 15, 2026
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
European equities traded in the US as American depositary receipts were heading lower late Tuesday m
NASDAQ · DBVT
Healthcare · Biotechnology
$11.79
Up+$0.03 (+0.26%)
Updated Sep 17, 2026, 10:21 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DBVT closed at $11.79 after 20 trading sessions, down 20.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $12.20 | $12.21 | $11.75 | $11.79 | 159.08K |
| Sep 15, 2026 | $12.20 | $12.2505 | $11.695 | $11.76 | 175.07K |
| Sep 14, 2026 | $12.20 | $12.62 | $11.92 | $12.35 | 269.58K |
| Sep 11, 2026 | $13.04 | $13.15 | $11.80 | $11.85 | 2.7M |
| Sep 10, 2026 | $13.51 | $13.51 | $12.93 | $12.97 | 125.35K |
| Sep 9, 2026 | $13.24 | $13.63 | $13.24 | $13.44 | 89.62K |
| Sep 8, 2026 | $13.40 | $13.465 | $13.14 | $13.27 | 181.29K |
| Sep 4, 2026 | $13.42 | $13.58 | $13.30 | $13.47 | 43.08K |
| Sep 3, 2026 | $13.90 | $13.90 | $13.44 | $13.70 | 145.25K |
| Sep 2, 2026 | $13.69 | $13.97 | $13.40 | $13.61 | 185.68K |
| Sep 1, 2026 | $13.58 | $13.72 | $13.09 | $13.42 | 250.61K |
| Aug 31, 2026 | $13.75 | $13.86 | $13.57 | $13.82 | 179.19K |
| Aug 28, 2026 | $14.38 | $14.38 | $13.45 | $13.54 | 146.15K |
| Aug 27, 2026 | $14.56 | $14.58 | $14.30 | $14.41 | 131.02K |
| Aug 26, 2026 | $14.67 | $14.71 | $14.14 | $14.52 | 242.52K |
| Aug 25, 2026 | $14.88 | $15.13 | $14.73 | $14.97 | 154.94K |
| Aug 24, 2026 | $14.28 | $14.36 | $13.98 | $14.14 | 122.74K |
| Aug 21, 2026 | $14.43 | $14.75 | $14.33 | $14.55 | 124.58K |
| Aug 20, 2026 | $14.42 | $14.7099 | $14.18 | $14.24 | 119.34K |
| Aug 19, 2026 | $15.09 | $15.10 | $14.47 | $14.78 | 263.23K |
The latest Smart Investors Daily articles mentioning DBVT.
DBVT research
Company profile and research snapshot.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2024 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Jun 16, 2024 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Mar 14, 2024 | SOCIETE GENERALE | Buy | — |
| Mar 13, 2024 | SOCIETE GENERALE | Buy | — |
| Dec 19, 2023 | PORTZAMPARC BNP PARIBAS | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 15, 2026
European equities traded in the US as American depositary receipts were heading lower late Tuesday m
Yahoo · Sep 2, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 DateTotal number of sharesTotal number of voting rights08/31/2026 314,388,807 Total gross of voting rights: 314,388,807 Total net* of voting rights: 314,222,095 * Net total = total number of voting rights attached to shares – shares without vo
Yahoo · Aug 26, 2026
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
Yahoo · Aug 25, 2026
European equities traded in the US as American depositary receipts were marginally higher late Tuesd
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning DBVT.